Microvascular Therapeutics
Business Services · Arizona, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1635 E 18th St, Tucson, Arizona, 85719, ...Phone Number
(520) 624-6688Website
www.mvtpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Microvascular Therapeutics
MVT Pharma is a biotechnology company that specializes in the development of microbubble and nanotechnology products aimed at enhancing the diagnosis and treatment of various diseases. They have pioneered ultrasound contrast agents and theranostics, with their flagship product, MVT-100, having completed Phase II clinical trials for echocardiography. The company is focused on innovative solutions for conditions such as brain cancer, myocardial microvascular obstruction, Alzheimer's disease, and breast cancer, utilizing advanced ultrasound technologies. MVT Pharma's intended clients include healthcare providers and institutions involved in diagnostic imaging and therapeutic interventions.Explore more
Microvascular Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Microvascular Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Microvascular Therapeutics launches new products
Funding: Get notified immidiatlly once Microvascular Therapeutics has new funding data
Microvascular Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Microvascular Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Microvascular Therapeutics had a recent Job posting/layoffs
Check out if Microvascular Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Microvascular Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Microvascular Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Microvascular Therapeutics
Compare insights from companies similar to Microvascular Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2014
MK
Michael KirbergerSenior Science Writer and Editor, SME, Patent Portfolio Manager
Company Profile Activity
Activity Insights
Microvascular Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Microvascular Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Microvascular Therapeutics.
Microvascular Therapeutics Tech Stack
A closer look at the technologies used by Microvascular Therapeutics
Microvascular Therapeutics News & Media
Microvascular Therapeutics: Positive Clinical Trial Results with Lead Candidate, CardiSon (MVT-100)
Microvascular Therapeutics, Inc. (MVT), a biotechnology company, announced that it has completed data analysis of its Phase II trial of its new ultrasound contrast agent, MVT-100, CardiSon, in echocardiography. In this study, 16 subjects received either the predicate agent Perflutren, or CardiSon, and echocardiographic imaging was performed. The echocardiograms were read and scored by three cardiologists blinded to the [PR.com]Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100
Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of MVT-100 in Healthy Volunteers, details of which can be found in ClinicalTrials.gov: NCT03882359. The initial results of the study [PR.com]Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. [PR.com]Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and Therapeutics, University of Pittsburgh, in collaboration with Microvascular Therapeutics (MVT), Inc., demonstrates the [PR.com]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Microvascular Therapeutics
Sign Up For FreeTo access detailed company insights
MVT Pharma is a biotechnology company that specializes in the development of microbubble and nanotechnology products aimed at enhancing the diagnosis and treatment of various diseases. They have pioneered ultrasound contrast agents and theranostics, with their flagship product, MVT-100, having completed Phase II clinical trials for echocardiography... Read More
